TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma

ConclusionsTERTp mutation appears be an indicator of both persistence and progression of structural disease after initial therapy in aggressive variants of TCDFC, and associates with a shorter progression free survival regardless of the therapy employed.

http://link.springer.com/10.1007/s12020-018-1642-0

Source: Endocrine - August 21, 2018 Category: Endocrinology Source Type: research